Texas-based ice cream manufacturer Blue Bell Creameries L.P. agreed to plead guilty to charges it shipped contaminated products linked to a 2015 listeriosis outbreak, and the company’s former president was charged in connection with a scheme to cover up the incident, the Justice Department announced.
In a plea agreement filed with a criminal information in federal court in Austin, Texas, Blue Bell agreed to plead guilty to two misdemeanor counts of distributing adulterated ice cream products and pay a criminal fine and forfeiture amount totaling $17.25 million. Blue Bell also agreed to pay an additional $2.1 million to resolve civil False Claims Act allegations regarding ice cream products manufactured under insanitary conditions and sold to federal facilities. The total $19.35 million in fine, forfeiture, and civil settlement payments constitutes the second largest-ever amount paid in resolution of a food-safety matter.
In a related case, Blue Bell’s former president, Paul Kruse, also was charged with seven felony counts related to his alleged efforts to conceal from customers what the company knew about the listeria contamination.
“American consumers rely on food manufacturers to take necessary steps to provide products that are safe to eat,” said Assistant Attorney General Jody Hunt of the Department of Justice’s Civil Division. “The Department of Justice will take appropriate action where food manufacturers ignore poor factory conditions or fail to abide by required recall procedures when problems are discovered.”
The plea agreement and criminal information filed today against Blue Bell in the U.S. District Court for the Western District of Texas alleges that the company distributed ice cream products that were manufactured under insanitary conditions and contaminated with Listeria monocytogenes, in violation of the Food, Drug and Cosmetic Act. According to the plea agreement, Texas state officials notified Blue Bell in February 2015 that two ice cream products from the company’s Brenham, Texas factory tested positive for Listeria monocytogenes, a dangerous pathogen that can lead to serious illness or death in vulnerable populations such as pregnant women, newborns, the elderly, and those with compromised immune systems. Blue Bell directed its delivery route drivers to remove remaining stock of the two products from store shelves, but the company did not recall the products or issue any formal communication to inform customers about the potential listeria contamination. Two weeks after receiving notification of the first positive listeria tests, Texas state officials informed Blue Bell that additional testing confirmed listeria in a third product. Blue Bell again chose not to issue any formal notification to customers regarding the positive tests.
In March 2015, tests conducted by the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) linked the strain of listeria in one of the Blue Bell ice cream products to a strain that sickened five patients at a Kansas hospital with listeriosis, the severe illness caused by ingestion of listeria-contaminated food. The FDA, CDC, and Blue Bell all issued public recall notifications on March 13, 2015. Subsequent tests confirmed listeria contamination in a product made at another Blue Bell facility in Broken Arrow, Oklahoma, which led to a second recall announcement on March 23, 2015.
“The health of American consumers and the safety of our food are too important to be thwarted by the criminal acts of any individual or company,” said Judith A. McMeekin, Pharm.D., Associate Commissioner for Regulatory Affairs, FDA. “Americans expect and deserve the highest standards of food safety and integrity and we will continue to pursue and bring to justice those who put the public health at risk by distributing contaminated foods in the U.S. marketplace.”
“This settlement demonstrates the commitment of the Defense Criminal Investigative Service and our law enforcement partners to hold companies accountable for failing to abide by important contract requirements,” said Robert E. Craig Jr., Special Agent in Charge of the DCIS Mid-Atlantic Field Office. “This case has been particularly concerning because of the disregard of basic food safety rules and the impact those actions can have on the health and safety of the Defense Department's service members and their families.”
“The health and safety of our military members and their families is critical to the Department of Defense and mission readiness,” said Michael C. Mentavlos, Special Agent in Charge of the DCIS Southwest Field Office. “We take all criminal acts, including those that raise grave health concerns, seriously, and DCIS will always place a premium on the well-being of our service members, their dependents, and our veterans.”
According to the plea agreement with the company, FDA inspections in March and April 2015 revealed sanitation issues at the Brenham and Broken Arrow facilities, including problems with the hot water supply needed to properly clean equipment and deteriorating factory conditions that could lead to insanitary circumstances. Blue Bell temporarily closed all of its plants in late April 2015 to clean and update the facilities. Since re-opening its facilities in late 2015, Blue Bell has taken significant steps to enhance sanitation processes and enact a program to test products for listeria prior to shipment.
According to the allegations filed against Kruse, Blue Bell’s former president allegedly orchestrated a scheme to deceive certain Blue Bell customers after he learned that products from the company’s Texas factory tested positive for Listeria monocytogenes. Kruse specifically is asserted to have directed other Blue Bell employees to remove potentially contaminated products from store freezers without notifying retailers or consumers about the real reason for the withdrawal. Kruse also is alleged to have directed employees to tell customers who asked why products were removed that there had been an unspecified issue with a manufacturing machine instead of that samples of the products had tested positive for listeria.
The civil False Claims Act settlement with the company resolves allegations that Blue Bell shipped ice cream products manufactured in insanitary conditions to U.S. facilities, and later failed to abide by contractually required recall procedures when its employees removed products from federal purchasers’ freezers without properly disclosing details about the potentially contaminated ice cream to the appropriate federal officials.
The allegations filed against Kruse merely assert that crimes have been committed. All defendants are presumed innocent until proven guilty beyond a reasonable doubt.
Except as admitted in the plea agreement, the False Claims Act claims resolved by the settlement with the company are allegations only and there has been no determination of liability.
The new nano GEN2 i-4.0 range of nitrogen gas generators provide a wide range of flow rates and purities from 95% to 9999%. The fourth Industrial Revolution has arrived as machines are digitally connected to their operators and the GEN2 i-4.0 leads the industry for onsite N2 gas generators. Full communication protocols including modbus, profibus and other building management system connections can be achieved via an RS485 or ethernet RJ45 port. The WiFi option allows the GEN2 i-4.0 can be accessed, operated and monitored from anywhere in the world.
With a nano GEN2 i-4.0 gas generator, the company said, payback can be expected typically between six and 24 months. The modular design and energy-saving functionality offers a number of benefits. The compact system can be installed easily and with a minimum cost and disruption and requires only a pre-treated compressed air system to start production. An on-site generator enables users to fulfill their demand for nitrogen gas on their premises, under their complete control. As a result, companies can generate as much or as little nitrogen as needed at a fraction of the cost of having the gas delivered by an external supplier, the company said
Food Safety Net Services (FSNS) is offering environmental swab testing for COVID-19 (SARS-CoV-2). The test method allows for the detection of the presence of COVID-19 (SARS-CoV-2) viral particles on environmental surfaces within production facilities. This new capability is intended to help companies better understand the effectiveness of their sanitation practices against the virus.
The viral transport swab kits are easy-to-use and come with step-by-step instructions for seamless submission to the FSNS laboratory, the company said. The turnaround time is 48 hours once the samples have been received. For more information, visit http://fsns.com/ or contact email@example.com or call 888-525-9788.
Soter Technologies’ team of engineers and medical advisors have created technology designed to help reduce the spread of the COVID-19 pandemic and other illnesses, and to aid in the re-opening of the economy. Soter Technologies has developed the SymptomSense Medical Evaluation Gateway, a non-invasive walk-through electronic full-body symptom scanner designed to detect symptoms of known illness in less than 10 seconds.
SymptomSense, now moving into production phase, is an electronic walk-through full-body health scanner that looks similar to metal detectors used at security checkpoints of airports. Similar to the rapid evaluation that an individual would receive at a hospital emergency room
SymptomSense uses an array of sensors to provide a rapid, non-invasive, hands-free approach for gaining important real-time vital signs, including blood oxygen levels, external body temperature within 0.2 degrees of accuracy (Celsius), elevated heart rate, respiration rate, shortness of breath, lung congestion, height, weight and, in the future, non-contact blood pressure. Within seconds the SymptomSense device provides health status with clear messaging and indicators for screening staff, and, in the future, data mapping of alerts to an electronic system-of-records that can be shared with authorities as may be required per local laws and ordinances, the company said.
The development and beta testing of prototypes started in late 2019 in response to the COVID-19 outbreak in China. The company formed an advisory board of doctors, scientists, and engineers that continues to work with the medical and research community to enhance the systems’ technology and capabilities. For example, SymptomSense now includes a module for weapons detection to provide property managers with an all-in-one access reassurance solution. Delivery of the first units is set for June 2020.
SymptomSense can scan approximately 1,500 people per hour and process more than 10,000 people over an eight-hour period, with zero downtime. An optional built-in facial recognition technology is available for data-mapping to government registry enabling site security personnel to track the movement of potential carriers of a virus, while protecting their privacy. This data capture and mapping capability is critical for understanding the current and predictive patterns, and trending for the spread of disease, and then helping trace back to most-current disease geo-location clustering and origin, the company said. As needed, the platform then can be linked to mobile phone “contact tracing” data, local weather data, and demographic data as may be required by government agencies.